论文部分内容阅读
目的:观察厄贝沙坦氢氯噻嗪片联合依那普利治疗扩张型心肌病(DCM)的疗效。方法:选择DCM 93例,随机分为观察组47例和对照组46例。观察组在常规治疗的基础上加服厄贝沙坦氢氯噻嗪片及依那普利,对照组仅加服依那普利。治疗后6个月,比较两组心率、血压水平及超声心动图各项指标变化情况。结果:观察组心率及收缩压和舒张压水平与对照组比较,差异均不显著(P>0.05);左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左心室射血分数(LVEF)与短轴缩短率(FS),较对照组均有显著改善(P<0.05)。结论:厄贝沙坦氢氯噻嗪片联合依那普利治疗DCM的疗效优于单用依那普利。
Objective: To observe the efficacy of irbesartan hydrochlorothiazide tablets combined with enalapril in the treatment of dilated cardiomyopathy (DCM). Methods: Ninety-three DCM patients were randomly divided into observation group (n = 47) and control group (n = 46). The observation group received irbesartan hydrochlorothiazide tablets and enalapril on the basis of routine treatment, while the control group only enalapril. Six months after treatment, heart rate, blood pressure and echocardiographic parameters were compared between the two groups. Results: There was no significant difference in heart rate, systolic pressure and diastolic blood pressure between the two groups (P> 0.05). LVEDV, (LVEF) and shortening rate of short axis (FS) were significantly improved compared with the control group (P <0.05). Conclusion: Irbesartan hydrochlorothiazide tablets combined with enalapril treatment of DCM is superior to enalapril alone.